Show simple item record

dc.contributor.authorXu, Daniel
dc.contributor.authorAffandi, Jacquita
dc.contributor.authorYap, Timothy
dc.contributor.authorReid, Christopher
dc.date.accessioned2020-07-16T05:59:22Z
dc.date.available2020-07-16T05:59:22Z
dc.date.issued2020
dc.identifier.citationXu, D. and Affandi, J. and Yap, T. and Reid, C. 2020. Metformin Use beyond Diabetes: Reducing Cardiovascular Events in the Healthy Elderly. Journal of Gerontology & Geriatric Medicine. 6 (058).
dc.identifier.urihttp://hdl.handle.net/20.500.11937/80075
dc.identifier.doi10.24966/GGM-8662/100058
dc.description.abstract

As the global ageing population rises, there is increasing interest and demand for research evaluating anti-ageing strategies. One such strategy involves investigating a drug that may have additional mechanisms and pathways of action to combat ageing - metformin. This common glucose-lowering agent for diabetes has been safe, effective and globally affordable for over 60 years. Research into the use of metformin and its beneficial influence on healthy ageing is currently emerging. Although metformin’s effect on clinical ageing outcomes may be speculative, findings from studies into cellular and animal models and from observational and pilot human studies support its potential beneficial effects on ageing. Ageing has a significant impact on the cardiovascular system and is the leading non-modifiable risk factor for Cardiovascular Disease (CVD). The incidence and prevalence of CVD increases with advancing age, and CVD is the leading cause of death for populations over 65 years of age. However, most CVD prevention research has focused on development of interventions that target “traditional” CV risk factors such as hypertension, hypercholesterolaemia and diabetes. Metformin has been proposed to be an “anti-ageing” drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for patients with type 2 diabetes. At present, randomised clinical trials to evaluate metformin’s clinical impact on healthy ageing are limited. Here, we review the role of metformin and its potential to reduce cardiovascular events in the healthy elderly.

dc.publisherPacini Editore s.r.l.
dc.relation.urihttps://www.heraldopenaccess.us/openaccess/metformin-use-beyond-diabetes-reducing-cardiovascular-events-in-the-healthy-elderly
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleMetformin Use beyond Diabetes: Reducing Cardiovascular Events in the Healthy Elderly
dc.typeJournal Article
dcterms.source.volume6
dcterms.source.number058
dcterms.source.issn2499-6564
dcterms.source.titleJournal of Gerontology & Geriatric Medicine
dc.date.updated2020-07-16T05:59:21Z
curtin.note

© Authors. Published in Journal of Gerontology & Geriatric Medicine.

curtin.departmentSchool of Public Health
curtin.accessStatusOpen access
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidReid, Christopher [0000-0001-9173-3944]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/